344 related articles for article (PubMed ID: 23860448)
1. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.
Puig N; Sarasquete ME; Balanzategui A; Martínez J; Paiva B; García H; Fumero S; Jiménez C; Alcoceba M; Chillón MC; Sebastián E; Marín L; Montalbán MA; Mateos MV; Oriol A; Palomera L; de la Rubia J; Vidriales MB; Bladé J; Lahuerta JJ; González M; Miguel JF; García-Sanz R
Leukemia; 2014 Feb; 28(2):391-7. PubMed ID: 23860448
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.
Silvennoinen R; Lundan T; Kairisto V; Pelliniemi TT; Putkonen M; Anttila P; Huotari V; Mäntymaa P; Siitonen S; Uotila L; Penttilä TL; Juvonen V; Selander T; Remes K
Blood Cancer J; 2014 Oct; 4(10):e250. PubMed ID: 25303369
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
[TBL] [Abstract][Full Text] [Related]
5. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
Martinez-Lopez J; Fernández-Redondo E; García-Sánz R; Montalbán MA; Martínez-Sánchez P; Pavia B; Mateos MV; Rosiñol L; Martín M; Ayala R; Martínez R; Blanchard MJ; Alegre A; Besalduch J; Bargay J; Hernandez MT; Sarasquete ME; Sanchez-Godoy P; Fernández M; Blade J; San Miguel JF; Lahuerta JJ;
Br J Haematol; 2013 Dec; 163(5):581-9. PubMed ID: 24117042
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
[No Abstract] [Full Text] [Related]
7. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.
Rasmussen T; Poulsen TS; Honoré L; Johnsen HE
Exp Hematol; 2000 Sep; 28(9):1039-45. PubMed ID: 11008016
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic significance of sequencing-based MRD detection in multiple myeloma].
Takamatsu H
Rinsho Ketsueki; 2015 Aug; 56(8):989-96. PubMed ID: 26345557
[TBL] [Abstract][Full Text] [Related]
10. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes.
Bai Y; Wong KY; Fung TK; Chim CS
J Hematol Oncol; 2016 Oct; 9(1):107. PubMed ID: 27724958
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.
Martinez-Lopez J; Lahuerta JJ; Pepin F; González M; Barrio S; Ayala R; Puig N; Montalban MA; Paiva B; Weng L; Jiménez C; Sopena M; Moorhead M; Cedena T; Rapado I; Mateos MV; Rosiñol L; Oriol A; Blanchard MJ; Martínez R; Bladé J; San Miguel J; Faham M; García-Sanz R
Blood; 2014 May; 123(20):3073-9. PubMed ID: 24646471
[TBL] [Abstract][Full Text] [Related]
12. Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.
Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Díaz MG; San Miguel JF; García-Sanz R
Eur J Haematol; 2012 Oct; 89(4):328-35. PubMed ID: 22805350
[TBL] [Abstract][Full Text] [Related]
13. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
14. Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients.
Sata H; Shibayama H; Maeda I; Habuchi Y; Nakatani E; Fukushima K; Fujita J; Ezoe S; Tadokoro S; Maeda T; Mizuki M; Kosugi S; Nakagawa M; Ueda S; Iida M; Tokumine Y; Azenishi Y; Mitsui H; Oritani K; Kanakura Y
Exp Hematol; 2015 May; 43(5):374-381.e2. PubMed ID: 25591497
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
Oliva S; Gambella M; Gilestro M; Muccio VE; Gay F; Drandi D; Ferrero S; Passera R; Pautasso C; Bernardini A; Genuardi M; Patriarca F; Saraci E; Petrucci MT; Pescosta N; Liberati AM; Caravita T; Conticello C; Rocci A; Musto P; Boccadoro M; Palumbo A; Omedè P
Oncotarget; 2017 Jan; 8(4):5924-5935. PubMed ID: 27779105
[TBL] [Abstract][Full Text] [Related]
18. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients.
Sedlarikova L; Kubiczkova L; Kryukov F; Pelcova J; Adam Z; Pour L; Hajek R; Sevcikova S
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):554-61. PubMed ID: 24993743
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.
Ladetto M; Brüggemann M; Monitillo L; Ferrero S; Pepin F; Drandi D; Barbero D; Palumbo A; Passera R; Boccadoro M; Ritgen M; Gökbuget N; Zheng J; Carlton V; Trautmann H; Faham M; Pott C
Leukemia; 2014 Jun; 28(6):1299-307. PubMed ID: 24342950
[TBL] [Abstract][Full Text] [Related]
20. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
